Surrozen, Inc. (SRZN) stock forecast & analysis
35.06
NasdaqCM · USD
Up: +1.38, +4.1%
1 analysis
- Open
- 34.72
- Previous close
- 33.68
- Day range
- 33.65 – 37.83
- 52-week range
- 11.39 – 37.83
- Volume (shares)
- 136.93K
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 11.75M
- P/E ratio
- Not available
- Dividend yield
- Not available
- Beta
- 0.56
- Market cap
- 412.08M
Market Scanner’s AI analysis of Surrozen, Inc. (SRZN), updated September 2026: Surrozen's drug pipeline advancement and strong revenue growth contrasted with ongoing unprofitability.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Surrozen, Inc. (SRZN) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
Surrozen's drug pipeline advancement and strong revenue growth contrasted with ongoing unprofitability.
Recent analyses of Surrozen (SRZN) covered significant year-over-year quarterly revenue growth and the submission of an Investigational New Drug (IND) application for a new compound. The reports also noted strong upward technical momentum and positive analyst initiation of coverage. However, the analyses also highlighted the company's current unprofitability and significant annual net losses.
SRZN news & sentiment
News reports highlighted a positive analyst initiation of coverage and the submission of a drug application, suggesting growing confidence in the company's pipeline. Social media sentiment tracked strong upward technical momentum and significant buying pressure.
SRZN technical picture
SRZN's stock exhibited strong upward momentum, trading significantly above its 50-day and 200-day SMAs. Momentum indicators like RSI and MFI signaled strong buying pressure, while the MACD trended upwards from previous lows. The price was trading above the upper Bollinger Band, suggesting potential overextension.
Fundamentals
The company reported significant year-over-year quarterly revenue growth, though annual revenue decreased from the prior year. Surrozen is currently unprofitable with negative operating margins and gross profit, alongside substantial annual net losses.
Factors discussed — upside
- 408.6% year-over-year quarterly revenue growth
- Submission of IND application for SZN-8141 compound
- William Blair initiated coverage with 'Outperform' rating
- Stock trading significantly above 50-day and 200-day SMAs
- RSI and MFI signaling strong buying pressure
Factors discussed — risks
- Company is currently unprofitable
- TTM operating margin is -385.3%
- TTM Gross Profit is -$23,066,000
- Significant annual net losses reported
- Price trading above upper Bollinger Band, indicating potential overextension
- Drug pipeline development
- Revenue growth
- Technical momentum
- Profitability
Summary updated .
SRZN technical indicators
Common technical indicators for SRZN, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 21.99 | Price above |
| 10-day exponential moving average | 23.25 | Price above |
| Relative strength index (14-day) | 78.26 | Overbought |
| MACD line (12/26/9) | 0.8542 | Above its signal line |
| Bollinger bands (20-day, 2σ) | 10.87 – 31.00 | Price above the upper band |
Analyses
Recent SRZN.US analyses are locked — sign in to read them or generate a fresh one.
Frequently asked questions
- What is the bull case for Surrozen, Inc.?
- Recent analyses highlighted Surrozen's significant year-over-year quarterly revenue growth and the advancement of its drug pipeline with the submission of an IND application for SZN-8141. The reports also noted strong upward technical momentum, with the stock trading well above key moving averages, and a positive initiation of coverage by William Blair.
- What are the risks for Surrozen, Inc.?
- The analyses also pointed to Surrozen's current unprofitability, characterized by a negative TTM operating margin and gross profit, alongside significant annual net losses. Additionally, the price trading above the upper Bollinger Band was noted, suggesting potential overextension.
- Is Surrozen, Inc. bullish or bearish?
- Recent AI analyses of Surrozen, Inc. examined factors on both sides. Discussed upside: Recent analyses highlighted Surrozen's significant year-over-year quarterly revenue growth and the advancement of its drug pipeline with the submission of an IND application for SZN-8141. The reports also noted strong upward technical momentum, with the stock trading well above key moving averages, and a positive initiation of coverage by William Blair. Discussed risks: The analyses also pointed to Surrozen's current unprofitability, characterized by a negative TTM operating margin and gross profit, alongside significant annual net losses. Additionally, the price trading above the upper Bollinger Band was noted, suggesting potential overextension. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Surrozen, Inc.?
- News reports highlighted a positive analyst initiation of coverage and the submission of a drug application, suggesting growing confidence in the company's pipeline. Social media sentiment tracked strong upward technical momentum and significant buying pressure.
- How does Market Scanner analyse Surrozen, Inc.?
- Every analysis of Surrozen, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
- Bundles used
- gemini-low-v2
Run a fresh SRZN.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.